Most weekly GLP-1 trials show a plateau between weeks 40 and 60, after which additional weight loss requires either dose escalation or fundamental adherence changes
Bottom line for endocrinologists: Noninvasive indices like FIB-4 may serve as integrated cardiometabolic risk stratification tools in patients with MASLD and T2DM bridging liver and cardiovascular care
Patients should stop tirzepatide and seek immediate medical care if they experience severe, persistent abdominal pain (which may indicate pancreatitis), symptoms of gallbladder disease (right upper quadrant pain, fever, jaundice), persistent vomiting leading to dehydration (which may cause acute kidney injury), or signs of severe allergic reaction
Safety, Regulation, and World Anti-Doping Agency Considerations Safety is a top concern
New England Journal of Medicine , 387(24), 2245-2257
The statements made about dietary supplements have not been evaluated by the FDA, and this product is not intended to diagnose, treat, cure, or prevent any disease